May Newsmakers, Including at ASCO

ASCO 2020 Newsmakers

Duke Cancer Institute presented more than 100 abstracts across multiple cancer types during the ASCO20 Virtual Scientific Program of the 2020 Annual Meeting of the American Society of Clinical Oncology — held May 29 to 31. The ASCO20 Virtual Education Program will be held August 8 to 10.

Conquer Cancer Foundation: Duke Fellow Receives 2020 Conquer Cancer Merit Award
Features Landon Brown, MD

Medicenna Updates Efficacy Results from Phase 2b Recurrent GBM Trial at ASCO 2020 (P & T Community)
Features John Sampson, MD, PhD

ASCO 2020: HERO Phase III Trial: Results Comparing Relugolix, an Oral GnRH Receptor Antagonist, versus Leuprolide Acetate for Advanced Prostate Cancer (Uro Today)
Features Daniel George, MD

Apalutamide, Darolutamide Both Yield OS Benefit in Nonmetastatic Prostate Cancer (ASCO Daily News)
Features Susan Halabi, PhD

Enzalutamide Approved by Japan MHLW for the Treatment of Prostate Cancer with Distant Metastasis (Uro Today)
Features Andrew Armstrong, MD, Msc

Vivor Announces Study Results Presented at the American Society of Clinical Oncology 2020 Annual Meeting (Press Release)
Features Yousuf Zafar, MD, MHS, FASCO

ASCO 2020: Abstract Recommendations From Dr. Jeffrey Kirshner for Symptoms and Survivorship (Oncology Practice Update)
Features study co-authored by Thomas LeBlanc, MD

LISTEN: #ASCO20 Virtual Scientific Program: Dr. John Sweetenham Highlights Compelling Abstracts Impacting Cancer Care (ASCO) Features study co-authored by Thomas LeBlanc, MD

Integrated Palliative, Oncology Care for AML Improves PROs (Journal of Clinical Pathways)
Features Thomas LeBlanc, MD

Palliative Care Improves Quality of Life in Patients With AML (ASCO Daily News)
Features Thomas LeBlanc, MD

ASCO 2020 Abstract/Poster/Paper Highlights

Landon Carter Brown, MD, medical oncology fellow at Duke Cancer Institute, presented with a Conquer Cancer ASCO Merit Award, delivered an oral presentation on his winning abstract:  "Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types."

Thomas LeBlanc, MD, with co-first author Areej El-Jawahri, MD (Mass General) delivered an oral presentation of their abstract "Multisite randomized trial of integrated palliative and oncology care for patients with acute myeloid leukemia (AML)."

Brent Hanks, MD, PhD, was the Discussant at the Clinical Science Symposium “Systems Biology Approaches to Immunotherapy Response and Toxicity” presentation entitled ‘Rise of the Machines: AI in Predicting Immunotherapy Outcomes’.

Tian Zhang, MD, MHS, was the Discussant for the Genitourinary Cancer—Kidney and Bladder poster discussion session — “Single agent targeted agents vs combinations with IO: what is the optimal future therapy in advanced urothelial cancer?”

April Salama, MD, was the Poster Discussant for “Characterizing Long Term Outcomes in Metastatic Melanoma in 2020.”

The following investigators, from Duke/DCI, are first authors:

Danielle M. Brander, MD: Prevalence, screening, treatment, and complications of osteoporosis and osteopenia in Medicare patients with chronic lymphocytic leukemia (CLL);

Jeffrey Melson Clarke, MD: Interim results from the OPTIMAL trial: A phase II clinical trial of combination nivolumab, ipilimumab, and taxane in patients with untreated metastatic non-small cell lung cancer (NSCLC).

Susan Faye Dent, MD: Understanding and predicting fatigue, cardiovascular (CV) decline & events after breast cancer treatment (UPBEAT): A prospective multi-center wake forest NCORP research-base study

Annick Desjardins, MD: Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).

Jeremy Meyer Force, DO: Identification of pathogenic ROS1 alterations in cell-free DNA (cfDNA) from patients with breast cancer

Cristina Gasparetto, MD: Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM)  and Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM)

Christopher Hoimes, DO, PhD: Phase Ib/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): Final results from the cisplatin (C)- eligible cohort of HCRN GU14-188 and KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC)

Elizabeth Howell, MD student: Patterns of inpatient palliative care consultation for patients with brain and spine metastases.

Jacob Kaufman, MD, PhD postdoctoral fellow: Interferon gamma resistance in setting of LKB1 loss: Phenotypic characterization and investigation of mechanism.

Thomas William LeBlanc, MD: A fork in the road: A mixed methods study exploring why older adults with acute myeloid leukemia choose different treatment paths

Haley Moss, MD, MBA: Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: Are some patients missing out?

Katherine B. Peters, MD, PhD: BMX-HGG: Phase II trial of newly diagnosed high-grade glioma treated with concurrent radiation therapy, temozolomide, and BMX-001

Jennifer Kay Plichta, MD, MS: Missing data in breast cancer: Relationship with survival in national database

Pradeep Poonnen, MD, Heme-Onc fellow:Cost-effectiveness of genomic profiling in veterans with metastatic lung adenocarcinoma.

Neal E. Ready, MD, PhD: Practice gaps and challenges integrating new immuno-oncology agents in the treatment of cancer patients in the United States: A mixed-method study

Emma Ryan, MD student: Venous thromboembolism prophylaxis in ambulatory cancer patients initiating chemotherapy: A cost-effectiveness analysis.

Marc D Ryser, MD: Ipsilateral invasive cancer risk after diagnosis with ductal carcinoma in situ (DCIS): Comparison of patients with and without index surgery

John H. Sampson, MD, PhD: MDNA55 survival in recurrent glioblastoma (rGBM) patients expressing the interleukin-4 receptor (IL4R) as compared to a matched synthetic control.

Daniel Spinosa, MD, OBGYN resident: Ovarian cancer clinical trials: Study the studies to terminate the terminations

Linda Sutton, MD: Perceptions of process barriers to lung cancer screening at community oncology programs

Aaron Tarnasky, MPH (MS student): A randomized controlled trial (RCT) testing a mobile application (app) to identify cancer treatment-related financial assistance

Christina D Williams, PhD: Comparison of characteristics and outcomes among veterans receiving first-line immunotherapy versus chemotherapy for stage IV non-small cell lung cancer.

Tian Zhang, MD, MHS: PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and Ipilimumab with VEGF TKI cabozantinib in metastatic untreated REnal Cell CancEr (Alliance A031704)

Download Duke at ASCO Booklet or View the list of Duke abstracts (organized by categories and with hyperlinks) via the Duke Cancer Institute website

Other May Newsmakers

WATCH: Justine Rutter of the Kris Wood Lab explains how understanding genetic tradeoffs with antagonistic pleiotropy informs therapeutic strategies against cancer (JRNL CLUB)

Expert Spotlight: Dr. Andrew Armstrong (The MedNet)

Expert Spotlight: Dr. Christopher Kelsey (The MedNet)

Yousuf Zafar, MD: Comforted by Community (Discover Durham)

Judd W. Moul, MD, FACS, on Triaging Patients with Prostate Cancer (Cancer Network)

Post-Pandemic Predictions About Cancer Disparities After COVID-19
Features Lola Fayanju, MD, MPHS, MA

Duke Researchers To Begin Slowly Returning to Their Labs, With Masks (Duke Today)

COVID-19 Engineering Response Team Assembles from Every Corner of Duke (Pratt School of Engineering)
Features Allan Kirk, MD

WATCH: Celebrating National Nurses Week with DCI (DCI YouTube)

May Papers

The dysregulated pharmacology of clinically relevant ESR1 mutants is normalized by ligand-activated WT receptor. Molecular Cancer Therapeutics. May 7, 2020. Kaitlyn J Andreano, Jennifer G Baker, Sunghee Park, Rachid Safi, Sandeep Artham, Steffi Oesterreich, Rinath Jeselsohn, Myles Brown, Sarah Sammons, Suzanne E Wardell, Ching-yi Chang, John D Norris and Donald P McDonnell.

A Phase 1b Dose-Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue Sarcoma. Clin Cancer Res. 2020 May 7.
Chawla SP, Goel S, Chow W, Braiteh F, Singh AS, Grilley Olson JE, Osada A, Bobe I, Riedel RF.

Incidence of Opioid-Associated Deaths in Cancer Survivors in the United States, 2006-2016A Population Study of the Opioid Epidemic. JAMA Oncology. May 7, 2020. Fumiko Chino, MD; Arif Kamal, MD, MBA, MHS; Junzo Chino, MD.

Environmental Quality and Invasive Breast Cancer. Cancer Epidemiol Biomarkers. April 1, 2020. Gearhart-Serna LM, Hoffman K, Devi GR.

Utilizing Real-World Evidence (RWE) to Improve Care in Chronic Lymphocytic Leukemia: Challenges and Opportunities. Current Hematologic Malignancy Reports. 2020. Prioty Islam & Anthony R. Mato.